{"id":"4ce134ce-fcd8-535c-85f3-ec335dee953f","stable_key":"8f12ba85-1a92-5337-a9c0-9cee9b3be90d:theanine-ogtt-null","predicate":"did_not_significantly_reduce","statement":"Theanine did not significantly reduce the primary peak-minus-baseline glucose endpoint.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"0930f2b4-d851-58e4-97c5-8b17c7cf4619","mechanism_event_label":"Animal transport mechanisms did not establish a significant human glucose effect in this trial.","subject":{"id":"33a051c5-dba8-53cd-8761-c53732c447e6","slug":"theanine","display_name":"L-Theanine","entity_type_key":"small_molecule"},"object":{"id":"50cb3788-8117-5120-84e4-938218cffc24","slug":"ogtt-peak-glucose-increment","display_name":"OGTT peak glucose increment over baseline","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"0930f2b4-d851-58e4-97c5-8b17c7cf4619","stable_key":"8f12ba85-1a92-5337-a9c0-9cee9b3be90d:theanine-ogtt-null-event","event_type":"observed_intervention","label":"Animal transport mechanisms did not establish a significant human glucose effect in this trial.","description":"Theanine did not significantly reduce the primary peak-minus-baseline glucose endpoint.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"33a051c5-dba8-53cd-8761-c53732c447e6","slug":"theanine","display_name":"L-Theanine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"50cb3788-8117-5120-84e4-938218cffc24","slug":"ogtt-peak-glucose-increment","display_name":"OGTT peak glucose increment over baseline","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/theanine-research/41845544.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"c52235640bebf5a00b45b96dd1af1bf1c6cc102cef6a1707711314f870b08e34\", \"start_char\": 0, \"end_char\": 1980, \"text_sha256\": \"c52235640bebf5a00b45b96dd1af1bf1c6cc102cef6a1707711314f870b08e34\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Fixed-sequence two-period oral glucose tolerance study","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"300 mg theanine 15 minutes before OGTT; untreated visit always first","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Not a randomized treatment order. Primary glucose endpoint was negative; urinary glucose and sodium trends were not statistically significant.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"L-Theanine research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"theanine","display_name":"L-Theanine","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"39 healthy humans","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Animal transport mechanisms did not establish a significant human glucose effect in this trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[theanine-p41845544] Clinical assessment of blood glucose responses to 300-mg dose of L-theanine, an amino acid unique to green tea, in a fixed-sequence, two-period trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41845544/ DOI: 10.1186/s40780-026-00562-6","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Blood glucose and urinary solutes","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"85ce018d-07fb-5fdf-9b94-66ba03886171","evidence_kind":"source_excerpt","locator":"Lines 1238-1249","start_line":1238,"end_line":1249,"excerpt":"### theanine-ogtt-null\nTheanine did not significantly reduce the primary peak-minus-baseline glucose endpoint.\nCondition category: normal\nnutrient_topic: L-Theanine research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: Animal transport mechanisms did not establish a significant human glucose effect in this trial.\norganism: 39 healthy humans\ntissue_or_cell_type: Blood glucose and urinary solutes\nexperimental_model: Fixed-sequence two-period oral glucose tolerance study\nlimitations: Not a randomized treatment order. Primary glucose endpoint was negative; urinary glucose and sodium trends were not statistically significant.\nexposure: 300 mg theanine 15 minutes before OGTT; untreated visit always first\nevidence_span: {\"source_cache\": \"artifacts/theanine-research/41845544.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"c52235640bebf5a00b45b96dd1af1bf1c6cc102cef6a1707711314f870b08e34\", \"start_char\": 0, \"end_char\": 1980, \"text_sha256\": \"c52235640bebf5a00b45b96dd1af1bf1c6cc102cef6a1707711314f870b08e34\"}\n[theanine-p41845544] Clinical assessment of blood glucose responses to 300-mg dose of L-theanine, an amino acid unique to green tea, in a fixed-sequence, two-period trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41845544/ DOI: 10.1186/s40780-026-00562-6","model_system":"Fixed-sequence two-period oral glucose tolerance study","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [theanine-p41845544] Clinical assessment of blood glucose responses to 300-mg dose of L-theanine, an amino acid unique to green tea, in a fixed-sequence, two-period trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41845544/ DOI: 10.1186/s40780-026-00562-6","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"e2bf3fc8-fc9a-5d50-937a-559a76f8be7d","stable_key":"import-8f12ba85-1a92-5337-a9c0-9cee9b3be90d","title":"L-Theanine: metabolism, neural signaling, nutrient connections and human outcomes (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"c78f2a1961da546cd8d3ae9131a16613aed0d1032904ca19175b0641647142c1","revision_id":"4ec64995-1e5b-5279-9102-f203cb2e29e5","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}